[go: up one dir, main page]

ES2180592T3 - Formulaciones en aerosol libres de clorofluorocarbonos. - Google Patents

Formulaciones en aerosol libres de clorofluorocarbonos.

Info

Publication number
ES2180592T3
ES2180592T3 ES95101762T ES95101762T ES2180592T3 ES 2180592 T3 ES2180592 T3 ES 2180592T3 ES 95101762 T ES95101762 T ES 95101762T ES 95101762 T ES95101762 T ES 95101762T ES 2180592 T3 ES2180592 T3 ES 2180592T3
Authority
ES
Spain
Prior art keywords
chlorofluorocarbonos
aerosol formulations
formulations free
free
aerosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95101762T
Other languages
English (en)
Inventor
Julianne Berry
Imtiaz A Chaudry
Joel A Sequeira
Michael Kopcha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24863572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2180592(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2180592T3 publication Critical patent/ES2180592T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/30—Materials not provided for elsewhere for aerosols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

UNA FORMULACION DE AEROSOL QUE CONTIENE FUROATO DE MOMETASONA Y, COMO PROPULSOR, 1,1,1,2-TETRAFLUORETANO Y QUE ES ADECUADA PARA EL TRATAMIENTO DEL ASMA MEDIANTE UNA ADMINISTRACION NASAL U ORAL.
ES95101762T 1991-06-10 1992-06-08 Formulaciones en aerosol libres de clorofluorocarbonos. Expired - Lifetime ES2180592T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71278991A 1991-06-10 1991-06-10

Publications (1)

Publication Number Publication Date
ES2180592T3 true ES2180592T3 (es) 2003-02-16

Family

ID=24863572

Family Applications (3)

Application Number Title Priority Date Filing Date
ES95101762T Expired - Lifetime ES2180592T3 (es) 1991-06-10 1992-06-08 Formulaciones en aerosol libres de clorofluorocarbonos.
ES95101761T Expired - Lifetime ES2158908T3 (es) 1991-06-10 1992-06-08 Formulaciones en aerosol sin clorofluorocarbonos.
ES02022987T Expired - Lifetime ES2269582T3 (es) 1991-06-10 1992-06-08 Formulaciones en aerosol sin clorofluorocarbonos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES95101761T Expired - Lifetime ES2158908T3 (es) 1991-06-10 1992-06-08 Formulaciones en aerosol sin clorofluorocarbonos.
ES02022987T Expired - Lifetime ES2269582T3 (es) 1991-06-10 1992-06-08 Formulaciones en aerosol sin clorofluorocarbonos.

Country Status (24)

Country Link
US (2) US6503482B1 (es)
EP (7) EP1736147A3 (es)
JP (1) JPH06508149A (es)
CN (1) CN1067579A (es)
AT (4) ATE226067T1 (es)
AU (1) AU2178992A (es)
CA (1) CA2111003A1 (es)
CZ (1) CZ271393A3 (es)
DE (4) DE69231991T2 (es)
DK (1) DK1277467T3 (es)
ES (3) ES2180592T3 (es)
FI (1) FI935463A7 (es)
HU (1) HUT67445A (es)
IE (1) IE921848A1 (es)
IL (1) IL102130A0 (es)
MX (1) MX9202751A (es)
NO (2) NO934499L (es)
NZ (1) NZ243062A (es)
OA (1) OA09827A (es)
PT (1) PT1277467E (es)
SK (1) SK140593A3 (es)
WO (1) WO1992022287A1 (es)
YU (1) YU59192A (es)
ZA (1) ZA924163B (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
ATE171865T1 (de) * 1991-12-12 1998-10-15 Glaxo Group Ltd Arzneimittel
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
ES2079210T3 (es) * 1991-12-12 1996-01-01 Glaxo Group Ltd Formulacion farmaceutica de aerosol.
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
NZ246421A (en) 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US20030103907A1 (en) * 1991-12-18 2003-06-05 Schultz Robert K. Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
AU699677B2 (en) * 1992-07-31 1998-12-10 Glaxo Group Limited Surfactant free aerosol formulations containing beclomathasone dipropionate
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
DE4322703A1 (de) * 1993-07-08 1995-01-12 Asta Medica Ag Druckgaspackungen unter Verwendung von Polyoxyethylen-glyceryl-fettsäureestern als Suspensionsstabilisatoren und Ventilschmiermittel
CA2178473C (en) * 1993-12-20 2004-08-24 Tsi-Zong Tzou Flunisolide aerosol formulations
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
AU709783B2 (en) * 1994-03-14 1999-09-09 Abbott Laboratories Aerosol drug formulations containing vitamin E
GB9405594D0 (en) * 1994-03-22 1994-05-11 Ici Plc Cooling compositions
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
DE69530325T2 (de) * 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
GB9526392D0 (en) * 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
DE19616573C2 (de) 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
DE69731473T2 (de) * 1996-05-09 2005-10-27 Amrad Operations Pty. Ltd., Richmond Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
CZ294064B6 (cs) * 1996-08-29 2004-09-15 Schering Corporation Aerosolový suspenzní přípravek mometazonfuroátu bez chlorfluorovaných uhlovodíků
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
AU726510B2 (en) * 1996-12-04 2000-11-09 Consort Medical Plc Pharmaceutical compositions and devices for their administration
EP0966958A4 (en) * 1997-03-14 2001-10-10 Fujisawa Pharmaceutical Co AEROSOL PREPARATION
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
EP1033991B1 (en) * 1997-10-09 2002-04-17 Schering Corporation Mometasone furoate suspensions for nebulization
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
MXPA05002248A (es) * 2002-08-27 2005-06-08 Schering Corp Procedimiento para producir formulaciones de inhalador de dosis medida.
KR101040581B1 (ko) 2002-10-31 2011-06-10 가부시키가이샤 한도오따이 에네루기 켄큐쇼 표시소자 및 그 제어 방법
PT1572622E (pt) * 2002-12-10 2006-08-31 Sepracor Inc Sal de levalbuterol
JP2007505136A (ja) * 2003-09-10 2007-03-08 マツプ・フアーマシユーテイカルズ・インコーポレーテツド ジヒドロエルゴタミンを肺吸入により体循環に送達するためのエアゾール製剤
KR20060106823A (ko) * 2003-10-20 2006-10-12 쉐링 코포레이션 약제학적 에어로졸 조성물
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
EP1711164B1 (en) * 2004-01-21 2010-03-24 Schering Corporation Method of treating acute rhinosinusitis
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
WO2007020204A2 (en) * 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
CA2641616A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
CN100446770C (zh) * 2007-01-10 2008-12-31 上海现代药物制剂工程研究中心有限公司 丙酸培氯米松水雾剂
ES2691033T3 (es) * 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
GB0712454D0 (en) 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
TW201010708A (en) * 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
JP6374682B2 (ja) * 2013-09-09 2018-08-15 花王株式会社 筋萎縮抑制剤
WO2016018892A1 (en) 2014-07-29 2016-02-04 3M Innovative Properties Company Method of preparing a pharmaceutical composition
AU2019285374A1 (en) * 2018-06-13 2021-01-28 Puff-Ah Pty Ltd Apparatus for use in delivering respiratory drugs

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (es) 1956-03-21 1900-01-01
US2885427A (en) 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
US3320125A (en) 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3261748A (en) 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US4129603A (en) 1978-02-07 1978-12-12 Imperial Chemical Industries Limited Manufacture of halogenated compounds
US4311863A (en) 1980-06-11 1982-01-19 E. I. Du Pont De Nemours & Company Process for the manufacture of 1,1,1,2-tetrafluoroethane
DE3260474D1 (en) 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
DE3246081A1 (de) * 1982-12-13 1984-06-14 G. Pohl-Boskamp GmbH & Co Chemisch-pharmazeutische Fabrik, 2214 Hohenlockstedt Nitroglycerin-spray
PT84439B (pt) * 1986-03-10 1989-10-04 Burghart Kurt Processo de preparacao de composicoes farmaceuticas a base de nifedipina
US4851595A (en) 1987-07-07 1989-07-25 E. I. Du Pont De Nemours And Company Liquid phase halogen exchange process for the manufacture of 1,1,1,2-tetrafluoroethane
US4967024A (en) 1988-06-23 1990-10-30 E. I. Du Pont De Nemours And Company Catalyzed hydrofluorination process
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828544D0 (en) 1988-12-07 1989-01-11 Ici Plc Chemical process
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
DE3905726A1 (de) 1989-02-24 1990-08-30 Hoechst Ag Druckgaspackung und treibmittel fuer aerosole
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
AU633584B2 (en) 1989-06-15 1993-02-04 Tokyo Tanabe Company Limited Aerosols of pyrido(1,2-a)pyrimidine compounds
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
ES2071306T3 (es) * 1990-03-23 1995-06-16 Minnesota Mining & Mfg El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas.
EP0536204B1 (en) * 1990-06-27 1994-04-06 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
NZ238749A (en) * 1990-06-28 1993-07-27 Glaxo Inc Aerosol inhalation drug formulations with 1,1,1,2-tetrafluoroethane as propellant and a perfluorinated surfactant
ES2096653T3 (es) * 1990-06-29 1997-03-16 Fisons Plc Composiciones de aerosol presurizado.
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
DE4038203A1 (de) * 1990-11-30 1992-06-04 Kali Chemie Pharma Gmbh Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
SK140493A3 (en) * 1991-06-10 1994-10-05 Schering Corp Non-chlorofluorocarbon aerosol formulations
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
ATE171865T1 (de) 1991-12-12 1998-10-15 Glaxo Group Ltd Arzneimittel
NZ246421A (en) 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
US5202110A (en) * 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants

Also Published As

Publication number Publication date
EP0518601A1 (en) 1992-12-16
MX9202751A (es) 1992-12-01
IE921848A1 (en) 1992-12-16
EP0653205A1 (en) 1995-05-17
EP0587790A1 (en) 1994-03-23
NO934499D0 (no) 1993-12-09
DE69231991D1 (de) 2001-09-13
DE69232818D1 (de) 2002-11-21
EP0656205B1 (en) 2001-08-08
YU59192A (sh) 1994-12-28
EP1736147A3 (en) 2007-10-17
CA2111003A1 (en) 1992-12-23
ATE339952T1 (de) 2006-10-15
IL102130A0 (en) 1993-01-14
EP0587790B2 (en) 2000-03-08
EP0656205A1 (en) 1995-06-07
EP1277467A2 (en) 2003-01-22
NZ243062A (en) 1993-09-27
EP0587790B1 (en) 1996-01-03
JPH06508149A (ja) 1994-09-14
EP0653205B1 (en) 2002-10-16
CN1067579A (zh) 1993-01-06
ES2269582T3 (es) 2007-04-01
ATE226067T1 (de) 2002-11-15
ES2158908T3 (es) 2001-09-16
EP1277467B1 (en) 2006-09-20
DE69233659D1 (de) 2006-11-02
WO1992022287A1 (en) 1992-12-23
ATE132368T1 (de) 1996-01-15
DE69231991T2 (de) 2002-04-04
HUT67445A (en) 1995-04-28
FI935463A0 (fi) 1993-12-07
ZA924163B (en) 1993-02-24
DE69207409D1 (de) 1996-02-15
CZ271393A3 (en) 1994-07-13
DE69232818T2 (de) 2003-06-18
NO934499L (no) 1993-12-09
EP1005860A1 (en) 2000-06-07
AU2178992A (en) 1993-01-12
DK1277467T3 (da) 2007-01-15
DE69233659T2 (de) 2007-09-13
US6503482B1 (en) 2003-01-07
ATE203900T1 (de) 2001-08-15
US6416743B1 (en) 2002-07-09
SK140593A3 (en) 1994-11-09
PT1277467E (pt) 2006-12-29
OA09827A (en) 1994-04-15
EP1736147A2 (en) 2006-12-27
FI935463L (fi) 1993-12-07
FI935463A7 (fi) 1993-12-07
EP1277467A3 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
ES2180592T3 (es) Formulaciones en aerosol libres de clorofluorocarbonos.
ATE134509T1 (de) Fluorchlorkohlenwasserstoffreie aerosolformulierungen
ES2133130B1 (es) Nueva formulacion de budesonida, su uso y recipiente que la contiene.
AR013614A1 (es) Nueva composicion que comprende una combinacion de esteroides, un kit que la contiene, el uso de la misma, el uso de dicho kit de formoterol y debudesonida en la fabricacion de un medicamento
BG102689A (bg) Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения
ES554967A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
ES2079210T3 (es) Formulacion farmaceutica de aerosol.
ES2145254T3 (es) Formulaciones de aerosoles que contienen flunisolida.
ES2064160T3 (es) Formulacion de aerosol que comprende 17,21-dipropionato de beclometasona.
ES2106360T3 (es) Formulaciones farmaceuticas de aerosol que contienen dipropionato de beclometasona.
MY101791A (en) New benzimidazole derivatives
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
ES2079943T3 (es) Composiciones acuosas en aerosol para la pulverizacion del cabello que tienen un contenido relativamente bajo en compuestos organicos volatiles.
ES2044912T3 (es) Composiciones farmaceuticas dotadas de actividad secuestrante para los acidos biliares, conteniendo colestiramina como principio activo, y procedimiento para su preparacion.
ES2134634T3 (es) Composiciones farmaceuticas y dispositivos para su administracion.
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
MX9301157A (es) Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2091183T3 (es) Metodo para mejorar el sueño.
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
AR017215A1 (es) Composiciones que contienen generadores de oxido nitrico y uso de dichos generadores para la preparacion de un medicamento util para el tratamiento detrastornos de ojo seco
ES2095531T3 (es) Derivados de 17-beta-aril- y 17-beta-heterociclil-5-beta,14-beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos.
ES2087178T3 (es) Disulfato de ws7622a, procedimiento para su preparacion y su uso.
AR006437A1 (es) Uso de monohidrocloruro de n-(endo-9-metil-9-azabiciclo [3.3.1]non-3-il)-1- metilimidazol-3-carboxamida, para la fabricacion de un medicamento para eltratamiento o la profilaxis de diarrea y una composicion farmaceutica que lo contiene
ES2062940B1 (es) Agente gastrocinetico, proceso para su preparacion y composiciones farmaceuticas que lo contengan.